Relationship between metformin and abdominal aortic aneurysm
Relationship between metformin and abdominal aortic aneurysm
复制标题
DOI：
10.1016/j.jvs.2019.08.270
复制
发表时间：
2020-03-01
影响因子：
4.3
通讯作者：
Lareyre, Fabien
中科院分区：
文献类型：
--
作者：
Raffort, Juliette;Hassen-Khodja, Reda;Lareyre, Fabien
腹主动脉瘤（AAA）是一种危及生命的疾病，在临床实践中仍然缺乏药物治疗。流行病学研究强调了使用降糖药物（包括二甲双胍）与AAA之间的负相关。二甲双胍以其降血糖作用而闻名，但其对代谢和炎症反应的作用使其成为几种心血管疾病的潜在治疗靶点。本文综述了二甲双胍与AAA之间关系的最新研究进展。基于二甲双胍对主动脉壁的已知作用，本文讨论了二甲双胍在AAA患者治疗中的转化应用和临床试验。
Abdominal aortic aneurysm (AAA) is a life-threatening disease and pharmacologic agents to treat the disease remain lacking for clinical practice. Epidemiologic studies have highlighted a negative association between the use of antidiabetic drugs, including metformin, and AAA. Metformin is well-known for its blood glucose-lowering effect, but its action on both metabolism and inflammatory response has led to propose it as a potential therapeutic target in several cardiovascular diseases. In this review, we summarize the current knowledge on the link between metformin and AAA. Based on the known effects of the drug on the aortic wall, translational applications and clinical trials investigating the interest of metformin in the management of patients with AAA are discussed.